ncorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market ("IPM"). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.
| IPO Opening Date | Apr 25, 2023 |
|---|---|
| IPO Closing Date | Apr 27, 2023 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹1 per share |
| IPO Price | ₹1026 to ₹1080 per share |
| Market Lot | 13 Shares |
| Min Order Quantity | 13 Shares |
| Listing At | BSE, NSE |
| Issue Size | 40,058,844 shares (aggregating up to ₹4,326.36 Cr) |
| Offer for Sale | 40,058,844 shares of ₹1 (aggregating up to ₹4,326.36 Cr) |
| QIB Shares Offered | Not more than 50% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| Basis of Allotment Date | May 3, 2023 |
|---|---|
| Initiation of Refunds | May 4, 2023 |
| Credit of Shares to Demat Account | May 5, 2023 |
| IPO Listing Date | May 8, 2023 |
Mankind Pharma IPO is a main-board IPO of 40,058,844 equity shares of the face value of ₹1 aggregating up to ₹4,326.36 Crores. The issue is priced at ₹1026 to ₹1080 per share. The minimum order quantity is 13 Shares.
The IPO opens on Apr 25, 2023, and closes on Apr 27, 2023.
Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
The Mankind Pharma IPO opens on Apr 25, 2023 and closes on Apr 27, 2023.
Mankind Pharma IPO lot size is 13 Shares.
You can apply in Mankind Pharma IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services.
The finalization of Basis of Allotment for Mankind Pharma IPO will be done on May 3, 2023, and the allotted shares will be credited to your demat account by May 5, 2023.
Check the IPO allotment status.
The Mankind Pharma IPO listing date is May 8, 2023.
To Bid online, you need
Demat Account and Pan card.
Login to SMC account and
select the Mankind Pharma IPO
Enter UPI Id & Mobile number
Place your number of bids
with the exchange
A UPI mandate is sent to your
UPI App to block your funds.
